Loading...
XNAS
LIVN
Market cap3.46bUSD
Dec 05, Last price  
63.36USD
1D
-0.85%
1Q
9.30%
Jan 2017
40.89%
IPO
-1.23%
Name

LivaNova PLC

Chart & Performance

D1W1MN
XNAS:LIVN chart
P/E
54.71
P/S
2.76
EPS
1.16
Div Yield, %
—
Shrs. gr., 5y
2.45%
Rev. gr., 5y
2.94%
Revenues
1.25b
+8.66%
103,442,570123,441,575130,968,437121,229,742143,600,979167,775,672190,464,398218,502,731254,320,417282,014,160291,557,9981,213,900,0001,012,300,0001,107,000,0001,084,200,000934,200,0001,035,400,0001,021,800,0001,153,545,0001,253,437,000
Net income
63m
+260.39%
-12,218,348-59,069,192-51,180,107-10,334,76526,720,62078,448,88446,725,71036,077,73246,357,50254,890,25757,847,534-62,800,000-25,100,000-189,400,000-155,500,000-343,300,000-135,700,000-86,200,00017,546,00063,234,000
CFO
183m
+144.33%
-3,969,672-70,876,209-20,688,85614,455,20724,589,95042,885,48649,872,10775,026,16579,053,75954,195,81679,675,11690,200,00091,300,000120,500,000-91,100,000-79,400,000102,500,00069,900,00074,914,000183,038,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
URL
https://www.livanova.com/en-us
IPO date
Oct 19, 2015
Employees
2,900
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT